Markets
MRK

Merck: CHMP Supports KEYTRUDA Plus Inlyta To Treat Advanced Renal Cell Carcinoma

(RTTNews) - Merck (MRK) said CHMP, the Committee of the European Medicines Agency, has recommended approval of KEYTRUDA plus Inlyta combination for the first-line treatment of patients with advanced renal cell carcinoma. The final decision by the European Commission is anticipated in the third quarter of 2019.

The CHMP recommendation is based on the results from the Phase 3 KEYNOTE-426 trial, which showed significant improvements in overall survival, progression-free survival and objective response rate for KEYTRUDA in combination with axitinib compared to sunitinib.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MRK

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More